Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia
Patients with asplenia are at high risks of severe infections caused by encapsulated bacteria, particularly Streptococcus pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) are recommended for invasive pneumococcal disease pr...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-10-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1943989 |
| _version_ | 1797673235600375808 |
|---|---|
| author | Kenichi Takeshita Noriko Takeuchi Yoshiko Takahashi Chie Fukasawa Haruka Hishiki Tadashi Hoshino Naruhiko Ishiwada Naoki Shimojo |
| author_facet | Kenichi Takeshita Noriko Takeuchi Yoshiko Takahashi Chie Fukasawa Haruka Hishiki Tadashi Hoshino Naruhiko Ishiwada Naoki Shimojo |
| author_sort | Kenichi Takeshita |
| collection | DOAJ |
| description | Patients with asplenia are at high risks of severe infections caused by encapsulated bacteria, particularly Streptococcus pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) are recommended for invasive pneumococcal disease prevention; however, little is known about the immunity to pneumococci in young patients with asplenia. We measured pneumococcal serotype-specific IgG (Pn-IgG) levels and pneumococcal opsonophagocytic activity (Pn-OPA) against some PCV13-contained serotypes (1, 3, 5, 6A, 7 F, 19A) in 23 young patients with asplenia using surplus serum samples. In this study, 5 and 13 patients had received PCV13 during routine immunizations and PPSV23, respectively; however, >5 years had passed since the last dose in most cases. The geometric mean concentrations (GMCs) of Pn-IgG in all study patients were not under the cutoff level against six serotypes, but they were lower than the those of age-matched healthy controls, as we have previously published. The patients who had received only PPSV23 had significantly lower GMCs against four serotypes (serotypes 1, 6A, 7 F, and 19A) than that of the patients who had received at least one PCV13 vaccination. The patients who had received only PPSV23 also had significantly lower geometric mean titers (GMTs) of Pn-OPA against all three serotypes we measured (serotypes 3, 5, and 19A) than that of the patients who had received at least one PCV13 vaccination. Our findings are useful data that can indicate insufficient immunity in young patients with asplenia against some PCV13 pneumococci serotypes and suggest the need for appropriate vaccinations in the post-PCV13 era. |
| first_indexed | 2024-03-11T21:42:37Z |
| format | Article |
| id | doaj.art-4a7d574d648a4661a3a9145ce729e3be |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:37Z |
| publishDate | 2021-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-4a7d574d648a4661a3a9145ce729e3be2023-09-26T12:47:03ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-10-0117103687369110.1080/21645515.2021.19439891943989Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with aspleniaKenichi Takeshita0Noriko Takeuchi1Yoshiko Takahashi2Chie Fukasawa3Haruka Hishiki4Tadashi Hoshino5Naruhiko Ishiwada6Naoki Shimojo7Chiba UniversityChiba UniversitySeikeikai Chiba Medical CenterChiba Children’s HospitalChiba UniversityChiba Children’s HospitalChiba UniversityChiba UniversityPatients with asplenia are at high risks of severe infections caused by encapsulated bacteria, particularly Streptococcus pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) are recommended for invasive pneumococcal disease prevention; however, little is known about the immunity to pneumococci in young patients with asplenia. We measured pneumococcal serotype-specific IgG (Pn-IgG) levels and pneumococcal opsonophagocytic activity (Pn-OPA) against some PCV13-contained serotypes (1, 3, 5, 6A, 7 F, 19A) in 23 young patients with asplenia using surplus serum samples. In this study, 5 and 13 patients had received PCV13 during routine immunizations and PPSV23, respectively; however, >5 years had passed since the last dose in most cases. The geometric mean concentrations (GMCs) of Pn-IgG in all study patients were not under the cutoff level against six serotypes, but they were lower than the those of age-matched healthy controls, as we have previously published. The patients who had received only PPSV23 had significantly lower GMCs against four serotypes (serotypes 1, 6A, 7 F, and 19A) than that of the patients who had received at least one PCV13 vaccination. The patients who had received only PPSV23 also had significantly lower geometric mean titers (GMTs) of Pn-OPA against all three serotypes we measured (serotypes 3, 5, and 19A) than that of the patients who had received at least one PCV13 vaccination. Our findings are useful data that can indicate insufficient immunity in young patients with asplenia against some PCV13 pneumococci serotypes and suggest the need for appropriate vaccinations in the post-PCV13 era.http://dx.doi.org/10.1080/21645515.2021.1943989aspleniaserotype specific igg levelopsonophagocytic activity13-valent pneumococcal conjugate vaccine23-valent pneumococcal polysaccharide vaccine |
| spellingShingle | Kenichi Takeshita Noriko Takeuchi Yoshiko Takahashi Chie Fukasawa Haruka Hishiki Tadashi Hoshino Naruhiko Ishiwada Naoki Shimojo Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia Human Vaccines & Immunotherapeutics asplenia serotype specific igg level opsonophagocytic activity 13-valent pneumococcal conjugate vaccine 23-valent pneumococcal polysaccharide vaccine |
| title | Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia |
| title_full | Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia |
| title_fullStr | Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia |
| title_full_unstemmed | Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia |
| title_short | Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia |
| title_sort | pneumococcal serotype specific igg and opsonophagocytic activity in young japanese patients with asplenia |
| topic | asplenia serotype specific igg level opsonophagocytic activity 13-valent pneumococcal conjugate vaccine 23-valent pneumococcal polysaccharide vaccine |
| url | http://dx.doi.org/10.1080/21645515.2021.1943989 |
| work_keys_str_mv | AT kenichitakeshita pneumococcalserotypespecificiggandopsonophagocyticactivityinyoungjapanesepatientswithasplenia AT norikotakeuchi pneumococcalserotypespecificiggandopsonophagocyticactivityinyoungjapanesepatientswithasplenia AT yoshikotakahashi pneumococcalserotypespecificiggandopsonophagocyticactivityinyoungjapanesepatientswithasplenia AT chiefukasawa pneumococcalserotypespecificiggandopsonophagocyticactivityinyoungjapanesepatientswithasplenia AT harukahishiki pneumococcalserotypespecificiggandopsonophagocyticactivityinyoungjapanesepatientswithasplenia AT tadashihoshino pneumococcalserotypespecificiggandopsonophagocyticactivityinyoungjapanesepatientswithasplenia AT naruhikoishiwada pneumococcalserotypespecificiggandopsonophagocyticactivityinyoungjapanesepatientswithasplenia AT naokishimojo pneumococcalserotypespecificiggandopsonophagocyticactivityinyoungjapanesepatientswithasplenia |